Literature DB >> 11166897

Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype.

J Nöjd1, T Tecle, A Samuelsson, C Orvell.   

Abstract

In April 1999, a previously healthy 22-year-old woman was taken ill with fever and bilateral swelling of the parotid glands. A chronic course of disease extending from April to December was found with swelling of the parotid glands, fatigue, low grade fever, episodes of tachycardia and nightswetting. Mumps virus RNA of genotype A character based on the SH (small hydrophobic) protein gene classification was demonstrated in three serum samples collected during the course of clinical disease. Different criteria for reinfection were fulfilled including demonstration of IgG antibodies by ELISA in a preinfection serum sample. The preinfection serum sample of the patient was able to efficiently neutralize the infectivity of a heterologous genotype D strain but was unable to neutralize the homologous genotype A virus. The findings in the present study may offer an explanation of a mechanism behind previously observed vaccine failures and the occurrence of reinfection with heterologous mumps virus strains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166897     DOI: 10.1016/s0264-410x(00)00392-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Recent mumps outbreaks in vaccinated populations: no evidence of immune escape.

Authors:  Steven A Rubin; Malen A Link; Christian J Sauder; Cheryl Zhang; Laurie Ngo; Bert K Rima; W Paul Duprex
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

3.  Factors influencing preclinical in vivo evaluation of mumps vaccine strain immunogenicity.

Authors:  B Halassy; T Kurtović; M Brgles; M Lang Balija; D Forčić
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Two successive outbreaks of mumps in Nova Scotia among vaccinated adolescents and young adults.

Authors:  Gaynor Watson-Creed; Andrea Saunders; Jeffrey Scott; Luis Lowe; Janice Pettipas; Todd F Hatchette
Journal:  CMAJ       Date:  2006-08-29       Impact factor: 8.262

5.  Immunogenicity of novel mumps vaccine candidates generated by genetic modification.

Authors:  Pei Xu; Zhenhai Chen; Shannon Phan; Adrian Pickar; Biao He
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

6.  Enzyme-linked immunospot assay detection of mumps-specific antibody-secreting B cells as an alternative method of laboratory diagnosis.

Authors:  Donald R Latner; Marcia McGrew; Nobia Williams; Luis Lowe; Roniel Werman; Eli Warnock; Kathleen Gallagher; Peter Doyle; Sandra Smole; Susan Lett; Noelle Cocoros; Alfred DeMaria; Raimond Konomi; Cedric J Brown; Paul A Rota; William J Bellini; Carole J Hickman
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

7.  Molecular identification of mumps virus genotypes from clinical samples: standardized method of analysis.

Authors:  G Palacios; O Jabado; D Cisterna; F de Ory; N Renwick; J E Echevarria; A Castellanos; M Mosquera; M C Freire; R H Campos; W I Lipkin
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

8.  Guidelines for the Prevention and Control of Mumps Outbreaks in Canada.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-01-04

9.  A 176 amino acid polypeptide derived from the mumps virus HN ectodomain shows immunological and biological properties similar to the HN protein.

Authors:  Emma Herrera; Patricia Barcenas; Rubicela Hernández; Alfonso Méndez; Guillermo Pérez-Ishiwara; Blanca Barrón
Journal:  Virol J       Date:  2010-08-20       Impact factor: 4.099

10.  Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus.

Authors:  John B Johnson; Gerald A Capraro; Griffith D Parks
Journal:  Virology       Date:  2008-04-28       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.